[
    [
        {
            "time": "2023-04-15",
            "original_text": "Big Pharma Stocks to Add to Your Portfolio This April",
            "features": {
                "keywords": [
                    "Big Pharma",
                    "Portfolio",
                    "April"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Big Pharma Stocks to Add to Your Portfolio This April",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-04-16",
            "original_text": "BMO’s Got A Point About Teva Stock, But Are Investors Willing To Listen?",
            "features": {
                "keywords": [
                    "BMO",
                    "Teva",
                    "Stock",
                    "Investors"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "BMO’s Got A Point About Teva Stock, But Are Investors Willing To Listen?",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-04-17",
            "original_text": "Arteaus Therapeutics Sells Emgality Royalty to Royalty Pharma for $260 Million",
            "features": {
                "keywords": [
                    "Arteaus",
                    "Therapeutics",
                    "Emgality",
                    "Royalty",
                    "Pharma",
                    "$260 Million"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Arteaus Therapeutics Sells Emgality Royalty to Royalty Pharma for $260 Million",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]